Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

Q3 2025 Earnings Call Transcript February 13, 2025 Operator: And good day. Thank you for standing by. Welcome to VistaGen ...

Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seventeen research firms that are currently covering the firm, Marketbeat ...

Equities research analysts at StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on ...

TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company ...

New research from The Lancet highlights persistent symptoms after the flu, similar to 'long Covid.' Veterans studied faced ...

The EPIC-B trial demonstrates the efficacy of cemiplimab monotherapy as a treatment for locally advanced or metastatic penile cancer (la/mPC). The trial met its primary endpoint, with a clinical ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...